Bradley Represents Castle Creek Biosciences, Inc. in Proposed Combination With Pelthos Therapeutics Inc.

BIRMINGHAM, AL—Bradley is serving as legal counsel to Castle Creek Biosciences, Inc. in connection with its definitive merger agreement with Pelthos Therapeutics Inc. (NYSE American: PTHS). Through the proposed combination, Castle Creek’s fibroblast-based cell and gene therapy platform would complement Pelthos’ portfolio of FDA-approved products and established dermatology commercial capabilities, with a focus on serious diseases that affect the skin. The definitive merger agreement provides for Castle Creek stockholders to receive 5.2 million shares of Pelthos common stock at closing, equivalent to approximately 32.5% of Pelthos’ fully diluted shares. Stockholders may also receive additional shares and milestone payments totaling up to $300 million, contingent on specified development and sales criteria and subject to the terms and conditions of the agreement.

The Bradley team advising Castle Creek on the transaction is led by corporate partners P. Gregory Hidalgo, Patrick M. Everman, P. Cyrus Chin, and Erin Reeves McGinnis, with support from associates Ashley J. Osborne and Hamza Mallick. The team also includes attorneys Marc Bussone, Michael S. Denniston, Stephen Hinton, Jake Neu, Eric Setterlund, Jennifer M. Trulock, Ryan P. Wheeler, and J. Michael Wilson.

Castle Creek is a late-stage company developing redosable gene therapies. It is preparing to advance the Phase 3 program of its lead candidate, D-Fi (FCX-007), for patients with dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease. The merger is positioned to expand the combined company’s pipeline of therapies and support the development of new treatments.

Following completion of the merger, the combined company will operate under the Pelthos Therapeutics Inc. name, with its shares continuing to trade on the NYSE American under PTHS. The companies’ October 30, 2026 announcement anticipated closing by the end of the first quarter of 2027, subject to customary closing conditions.

Bradley is serving as legal advisor to Castle Creek Biosciences, Inc., alongside Katten Muchin Rosenman LLP, while PHCP, LLC is serving as financial advisor. Latham & Watkins LLP is serving as legal advisor to Pelthos Therapeutics Inc.

The post Bradley Represents Castle Creek Biosciences, Inc. in Proposed Combination With Pelthos Therapeutics Inc. appeared first on Attorney at Law Magazine.